Major Shareholder Reduces Stake by $114M Amidst High Stock Price
RPRX sits 52% above its 52-week low of $29.66.
Summary
A significant shareholder, R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini, reported selling approximately $114 million worth of Royalty Pharma plc shares, reducing their beneficial ownership to 5.7%.
Key Events · Ownership and Investor Activity · RPRX
-
Significant Share Sales Reported
Reporting persons sold approximately 2.7 million shares of Royalty Pharma plc for a total of $113.9 million through open market transactions between November 2025 and February 2026.
-
Beneficial Ownership Reduced
The aggregate beneficial ownership of the reporting persons decreased to 24,223,082 Class A shares, representing 5.7% of the outstanding shares as of February 19, 2026.
-
Restructuring of Facility Agreements
The filing details a reduction in the number of Class A shares pledged as collateral and a decrease in committed/uncommitted facility amounts under existing financing agreements for MGG Strategic and GG Strategic.
Analysis · RPRX · Life Sciences
This Schedule 13D/A filing reveals that a major institutional investor, R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini, has significantly reduced its stake in Royalty Pharma plc. The reporting persons sold approximately 2.7 million shares for a total of $113.9 million between November 2025 and February 2026. These sales occurred while Royalty Pharma's stock was trading near its 52-week high, suggesting a strategic move to lock in gains or rebalance their portfolio. While the sellers are financial investors rather than operational insiders, the substantial dollar value of the sales could create an overhang on the stock. Additionally, the filing details a reduction in shares pledged as collateral and a decrease in available facility amounts, indicating a restructuring of the investor's financing arrangements.
At the time of this filing, RPRX was trading at $45.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26B. The 52-week trading range was $29.66 to $46.14. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.